Moderna is exploring partnerships in China to broaden its scope, CEO Stephane Bancel told Nikkei Asia. The company aims to bring its mRNA technology to the world's second-largest pharmaceutical market, navigating U.S. political pushback and intellectual property risks.
Moderna's pursuit of partnerships in China highlights the significant market opportunities and complex geopolitical challenges faced by Western companies. Success could provide a substantial boost to Moderna's revenue, particularly amid slowing COVID-19 vaccine sales, while navigating these risks is crucial for protecting its intellectual property and future growth.
Moderna, known for its COVID-19 vaccine, is actively seeking partnerships in China to expand its business, according to CEO Stephane Bancel. The company aims to leverage its messenger RNA technology for developing medicines in the world's second-largest pharmaceutical market. Bancel stated that while discussions are ongoing, Moderna does not intend to transfer its proprietary technology to Chinese partners. To mitigate risks, the company has implemented enhanced security measures to protect its intellectual property. However, these efforts face challenges, including U.S. political scrutiny, with Senator Marco Rubio publicly criticizing Moderna's interest in China. Bancel acknowledged that geopolitical tensions have made operating in China more complex.
Pick the topics you care about. Get only what matters, on your cadence.